UNASSIGNED: @entity3791 is one of the most widely used drugs for lowering @entity428 ( @entity428 ) and is believed to reduce cerebrospinal fluid (CSF) secretion via its action on the @entity2846 ( @entity2846 ). In the @entity2846 the main driving force for CSF secretion is primarily active transport of @entity4024 ions facilitated by the @entity4024 / @entity3529 ATPase. Transmembrane water channels, known as aquaporins (AQP), are also present in the @entity2846 and play an important role in the movement of water. In the present study, we investigated the effect of a single dose @entity3791 on the activity of the @entity4024 / @entity3529 ATPase and @entity428 . Furthermore, we investigated the expression of @entity4024 / @entity3529 ATPase, @entity6095 and @entity6096 in the @entity2846 tissue following @entity3791 treatment. 12 female @entity35 were randomized into two groups; one group received 200mg @entity3791 and the other vehicle treatment. All animals were subjected to @entity428 recordings and the @entity2846 tissue was collected for qPCR and western blot analysis. The effect of @entity3791 on the @entity4024 / @entity3529 ATPase activity was evaluated in an in vitro assay of primary @entity2846 epithelial cells isolated from @entity35 . @entity3791 significantly lowered @entity428 within 10minutes of injection compared to the vehicle group (P<0.05), reaching a maximum reduction at 55minutes 66  4% (P<0.00001). @entity3791 also significantly decreased the activity of the @entity4024 / @entity3529 ATPase in @entity2846 epithelial cells compared to vehicle (P=0.0022). @entity3791 did not change the @entity6095 , @entity6096 or @entity4024 / @entity3529 ATPase mRNA content in the @entity2846 tissue. However, we did record an increase in the amount of @entity6095 (p=0.0152) and @entity4024 / @entity3529 ATPase (p=0.0411) protein in the membrane fraction of the @entity2846 , but not @entity6096 (p=0.0649). A single dose of @entity3791 lowers @entity428 and modulates the CSF secretion pathway in healthy @entity35 - Firstly, by inhibiting the @entity4024 / @entity3529 ATPase to slow the CSF production, secondly, by increasing @entity6095 and @entity4024 / @entity3529 ATPase protein in the membrane of the @entity2846 epithelial cells.

@entity3791 Lowers Intracranial Pressure and Modulates the Cerebrospinal Fluid Secretion Pathway in Healthy XXXX .

@entity3529 :: ('D011188', 'Chemical') :: ['K'] @entity4024 :: ('D012964', 'Chemical') :: ['Na(+)', 'Na'] @entity428 :: ('MESH:D019586', 'Disease') :: ['ICP', 'intracranial pressure'] @entity3791 :: ('MESH:D000086', 'Chemical') :: ['acetazolamide', 'Acetazolamide'] @entity6095 :: ('25240(Tax:10116)', 'Gene') :: ['AQP1'] @entity6096 :: ('25293(Tax:10116)', 'Gene') :: ['AQP4'] @entity2846 :: ('MESH:D020288', 'Disease') :: ['choroid plexus', 'CP'] @entity35 :: ('10116', 'Species') :: ['Sprague Dawley rats', 'rats']
@entity35 :: (10116,Species) :: ['Rats']
